https://www.bioworld.com/rss en-us Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its pipeline and geographic reach across Asia Pacific. http://www.bioworld.com/articles/731721 Wed, 10 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731721-three-deals-in-six-days-everest-builds-late-stage-apac-portfolio Hands holding gears Total biopharma financing through the first five months of 2026 reached $49.46 billion, the third-highest total for the period in the dataset and more than doubling of 2025’s $21.4 billion over the same stretch. http://www.bioworld.com/articles/731832 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731832-hemab-soars-89-on-debut-as-biopharma-ipos-stay-strong-in-may Gray and green glass dollar symbols with arrow pointing up After a major breach of trust when its data were advertised for sale in China, the UK Biobank will now attempt to recall data previously downloaded by legitimate researchers and seek assurances information has been deleted from local servers. http://www.bioworld.com/articles/731831 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731831-uk-biobank-seeks-to-recall-downloads-after-health-data-breach Data breach - red broken padlock Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results. http://www.bioworld.com/articles/731830 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731830-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer Gastric cancer If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731829 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731829-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said. http://www.bioworld.com/articles/731828 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731828-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios Deal handshake with coin, chart background The recent introduction of the bipartisan Biotech Investment National Security Act in the U.S. House has industry and venture capitalists urging lawmakers to take a breath, step back, and consider a less invasive approach than restricting U.S. biopharma deals with Chinese innovators. http://www.bioworld.com/articles/731827 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731827-competitive-approach-better-than-restricting-deals-with-china China U.S. handshake China’s National Medical Products Administration (NMPA) on June 4 granted conditional approvals to two oncology drugs from Lupeng Pharmaceutical Co. Ltd. and Vcare Pharmatech Co. Ltd., as well as one hemophilia drug developed by Staidson Biopharmaceutical Co. Ltd. http://www.bioworld.com/articles/731712 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731712-nmpa-gives-conditional-nods-to-drugs-by-lupeng-vcare-staidson Red wooden approved stamp Japan has granted marketing approval to Oncolys Biopharma Inc.’s oncolytic adenovirus product, Telomelysin (suratadenoturev, OBP-301), for treating esophageal cancer in patients who are not eligible for curative resection or chemoradiotherapy. The approval marks the first oncolytic adenovirus product approved for esophageal cancer. http://www.bioworld.com/articles/731711 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731711-japan-backs-oncolys-virus-therapy-for-esophageal-cancer Illustration of cancer on the esophagus Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military company,” which makes it a “biotechnology company of concern” under the Biosecure Act. “Such designation is mistaken and baseless,” the global contract research, development and manufacturing organization said in an open letter to its life sciences partners. “We will pursue every available avenue to correct this mistake.” That includes appealing the designation. http://www.bioworld.com/articles/731710 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731710-wuxi-apptec-insists-its-not-a-chinese-military-company Wuxi Apptec signage Credit: Wuxi Apptec The recent introduction of the bipartisan Biotech Investment National Security Act in the U.S. House has industry and venture capitalists urging lawmakers to take a breath, step back, and consider a less invasive approach than restricting U.S. biopharma deals with Chinese innovators. http://www.bioworld.com/articles/731692 Mon, 08 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731692-competitive-approach-better-than-restricting-deals-with-china China U.S. handshake If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731634 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731634-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said. http://www.bioworld.com/articles/731632 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731632-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios Deal handshake with coin, chart background After a major breach of trust when its data were advertised for sale in China, the UK Biobank will now attempt to recall data previously downloaded by legitimate researchers and seek assurances information has been deleted from local servers. http://www.bioworld.com/articles/731631 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731631-uk-biobank-seeks-to-recall-downloads-after-health-data-breach Data breach - red broken padlock Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results. http://www.bioworld.com/articles/731617 Thu, 04 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731617-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer Gastric cancer D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day. http://www.bioworld.com/articles/731650 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731650-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025. http://www.bioworld.com/articles/731649 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731649-bms-hengrui-deal-strikes-panic-in-washington U.S. Capitol building China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards. http://www.bioworld.com/articles/731647 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731647-china-launches-long-awaited-drug-data-protection-rules Cybersecurity data lock Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody. http://www.bioworld.com/articles/731646 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731646-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing. http://www.bioworld.com/articles/731645 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731645-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly Hanmi signage Credit: Hanmi Pharmaceutical Co. Ltd. Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology. http://www.bioworld.com/articles/731644 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731644-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal Antibodies attacking cancer cell Less than two months after winning FDA approval for a second indication for Filspari (sparsentan), Travere Therapeutics Inc. added to its rare kidney disease pipeline by exclusively licensing civorebrutinib from Everest Medicines Ltd. in a deal that could be worth more than $1.14 billion. http://www.bioworld.com/articles/731526 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731526-travere-expands-rare-kidney-portfolio-in-1b-everest-deal 3D illustration of kidney cross section The U.S. FDA approved Shionogi & Co. Ltd.’s Xocova (ensitrelvir) as the first oral post-exposure prophylactic option in the U.S. to prevent COVID-19, with the decision coming ahead of a PDUFA target date of June 16. http://www.bioworld.com/articles/731531 Tue, 02 Jun 2026 08:00:00 -0400 https://www.bioworld.com/articles/731531-fda-clears-shionogis-xocova-as-first-covid-19-prevention-pill Xocova blister pack Credit: Shionogi & Co. Ltd. In 2025, China’s outbound life sciences and biopharma deals reached nearly $100 billion, about 12 times the level seen in 2021, underscoring how quickly global appetite for Chinese assets has accelerated, according to a recent report by L.E.K. Consulting. http://www.bioworld.com/articles/731530 Tue, 02 Jun 2026 08:00:00 -0400 https://www.bioworld.com/articles/731530-china-deals-highlight-biopharma-evolution-reports-lek China map/flag with silhouettes of business people Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top cancer immunotherapy for patients with non-small-cell lung cancer with bispecific antibodies targeting PD-(L)1 and VEGF. http://www.bioworld.com/articles/731513 Mon, 01 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731513-asco-2026-pd-l1-x-vegf-bispecifics-fight-it-out Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing. http://www.bioworld.com/articles/731459 Mon, 01 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731459-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly Hanmi signage Credit: Hanmi Pharmaceutical Co. Ltd. Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology. http://www.bioworld.com/articles/731458 Fri, 29 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731458-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal Antibodies attacking cancer cell China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards. http://www.bioworld.com/articles/731457 Fri, 29 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731457-china-launches-long-awaited-drug-data-protection-rules Cybersecurity data lock On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025. http://www.bioworld.com/articles/731574 Fri, 29 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731574-bms-hengrui-deal-strikes-panic-in-washington U.S. Capitol building Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. http://www.bioworld.com/articles/731648 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731648-trop2-adcs-progress-into-first-line-for-lung-breast-cancers Floating antibody drug conjugates